Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation May 04, 2022 7:30am EDT
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation May 02, 2022 4:10pm EDT
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022 Apr 25, 2022 7:30am EDT
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference Mar 31, 2022 7:30am EDT
